Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Aditi R. Saxena, Juan P. Frías, Lisa Brown, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314493-e2314493
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 10, pp. 877-888
Closed Access | Times Cited: 211
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 109
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3789-3820
Closed Access | Times Cited: 34
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 29
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Chuyu Yun, Sen Yan, Baoying Liao, et al.
Nature Metabolism (2024) Vol. 6, Iss. 5, pp. 947-962
Closed Access | Times Cited: 26
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 27
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Rosa F Drummond, Karl Seif, E. Albert Reece
American Journal of Obstetrics and Gynecology (2024) Vol. 232, Iss. 1, pp. 17-25
Closed Access | Times Cited: 15
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 12
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 11
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Xuetao Chen, Shicheng Xu, Shuang Yang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Jiahua Zhang, Jintao Wei, Weiwen Lai, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1651-1651
Open Access | Times Cited: 1
G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential
Y. Cho, Soyeon Kim, Pan-Kyung Kim, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 291-291
Open Access | Times Cited: 1
Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Jingxing Li, Tzu-Ju Hsu, Heng-Jun Lin, et al.
JAMA Network Open (2025) Vol. 8, Iss. 3, pp. e252577-e252577
Open Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara, A Mazumder, Yusra Syeda, et al.
Advances in Medicine (2023) Vol. 2023, pp. 1-7
Open Access | Times Cited: 18
Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action
Dan M. Cooper, Mark A. Rothstein, Alpesh Amin, et al.
Journal of Clinical and Translational Science (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Prathima Gogineni, Eka Melson, Dimitris Papamargaritis, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 7, pp. 801-818
Open Access | Times Cited: 8
A revolution in obesity treatment
Ildiko Lingvay, Shubham Agarwal
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2406-2408
Closed Access | Times Cited: 16
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri, Andrés Acosta
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1153-1164
Closed Access | Times Cited: 14
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116245-116245
Open Access | Times Cited: 5
Cryo-electron microscopy-based drug design
Ecenur Cebi, Joohyun Lee, Vinod Kumar Subramani, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 5
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Janet B. McGill, Irl B. Hirsch, Christopher G. Parkin, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1085-1098
Open Access | Times Cited: 5
Binding sites and design strategies for small molecule GLP-1R Agonists
Haibo Zhang, Tianxiao Wu, Yong Wu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116632-116632
Closed Access | Times Cited: 5
Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice
Michael Camilleri, Camille Lupiañez-Merly
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 6, pp. 1028-1037
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top